Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 6/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.32 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151259 | 0.91 | NAMPT (0.34) | TACR1NAMPT | |
| SCHEMBL21151158 | 0.89 | NAMPT (0.33) | TACR1NAMPTFABP7 | |
| SCHEMBL21150845 | 0.89 | NAMPT (0.34) | TACR1LIMK1LIMK2NAMPTGPR142 | |
| SCHEMBL21151201 | 0.89 | MCHR1 (0.38) | NAMPT | |
| SCHEMBL21150858 | 0.88 | NAMPT (0.36) | NAMPTFABP7 | |
| SCHEMBL21151272 | 0.88 | MAPK1 (0.32) | TACR1NAMPT | |
| SCHEMBL24974528 | 0.87 | MAPK1 (0.33) | TACR1NAMPTSCN9A | |
| SCHEMBL21150848 | 0.87 | NAMPT (0.34) | TACR1LIMK1LIMK2NAMPTFABP7 | |
| SCHEMBL21151783 | 0.87 | NAMPT (0.33) | TACR1LIMK1LIMK2KITNAMPT | |
| SCHEMBL21151315 | 0.86 | NAMPT (0.35) | TACR1NAMPTFABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | ENPP2 250/4885TACR1 76/4885GLS 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.